Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times UK
International Business Times UK
Health
Chelsie Napiza

GLP-1 Drugmakers Face Lawsuits as Patients Claim Ozempic and Wegovy Led To Rare Permanent Vision Loss

Hundreds of lawsuits against Novo Nordisk and Eli Lilly allege GLP-1 drugs caused NAION, a rare eye condition linked to sudden and potentially permanent vision loss (Credit: Towfiqu barbhuiya / Unsplash)

Hundreds of lawsuits have been filed against the makers of widely used weight-loss and diabetes drugs, alleging the medicines caused a rare eye condition that can lead to sudden and potentially permanent vision loss.

The cases target Novo Nordisk and Eli Lilly over several GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, and centre on non-arteritic anterior ischaemic optic neuropathy, known as NAION.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.